metabotropic glutamate receptor

(redirected from Mglur)

metabotropic glutamate receptor

A G protein-coupled receptor that mediates its effects by enzyme activation.
mGluRs can be subdivided into three groups (I–III) according to their sequence similarity, transduction mechanism and pharmacological profile.
References in periodicals archive ?
Inhibition of mGluR is a promising therapeutic strategy for autism disorders, including Fragile X, but the brain region responsible for this effect is not known.
The newly founded company will develop the mGluR programs from lead optimization up to clinical Phase I and seek partnership and licensing opportunities for further development.
With Preso1 so pivotal for regulating group 1 mGluR activity, it could prove a useful new target for drugs to treat a variety of health problems in which these receptors are thought to play a role, including chronic pain, schizophrenia, Alzheimer's disease, and fragile X syndrome, Worley added.
From his studies in both areas, Stern knew two things: PI3K/Tor was the major pathway for insulin signals within cells, and insulin could affect synapses in a remarkably similar way to the mGluR defects associated with autism.
Queen and colleagues (1993) found a reduction in mGluR function in the hippocampus of adult offspring from rats exposed to ethanol during pregnancy (at a blood ethanol level of 0.
2004) The mGluR theory of fragile X mental retardation, Trends in Neurosciences, 27(7), pp.
The paper, "Fragile X Syndrome (FXS) - an update on developing treatment modalities," was published online in the journal ACS Chemical Neuroscience and includes a discussion of the mGluR theory of fragile X syndrome.
MGluR is located on the surface of neurons, including in the hippocampus - a major memory and learning center in the brain.
Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: Potential insight into their anti-addictive properties.
We believe that the same mechanism is perturbed in PTSD and that mGluR could provide a potential target for therapeutic intervention," explained the author.
Members of these latter two mGluR subgroups reside predominantly on presynaptic axon terminals, where they act to inhibit neurotransmitter release (Coutinho and Knopfel 2002).
patent 6,890,931 B2 ('931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome, the most common known cause of autism, with group 1 antagonists of the mGluR pathway.